TABLE 2.

Hazard ratios with 95% confidence intervals and p‐values for associations between genes with a mutation frequency ≥3% and relapse‐free survival

Gene	Hazard ratio a	95% LCL	95% UCL	p‐Value	Gene	Hazard ratio a	95% LCL	95% UCL	p‐Value
KRAS	1.66	1.13	2.45	0.011	ARID1B	1.39	0.56	3.47	0.477
COL6A3	0.35	0.13	0.95	0.04	KIF2B	1.41	0.51	3.85	0.508
RNF43	2.17	0.98	4.79	0.055	ERBB2	0.7	0.22	2.24	0.543
NOTCH3	0.18	0.03	1.33	0.093	ALK	0.7	0.22	2.22	0.545
SOX9	0.55	0.27	1.16	0.116	FAT1	0.76	0.31	1.88	0.553
ERBB3	1.68	0.77	3.69	0.193	VCAN	0.74	0.27	2.03	0.554
MLL2	0.55	0.22	1.36	0.195	BRCA2	1.3	0.53	3.23	0.566
CTNNB1	1.64	0.74	3.6	0.223	NRAS	0.76	0.28	2.07	0.587
DLC1	0.42	0.1	1.73	0.233	EPHA3	1.23	0.56	2.72	0.605
FAT4	0.7	0.38	1.28	0.242	ABCA12	0.82	0.36	1.88	0.64
GPC6	0.44	0.11	1.8	0.254	MYH11	1.24	0.5	3.08	0.644
MLL3	1.7	0.67	4.27	0.262	GNAS	0.87	0.45	1.69	0.673
PDGFRA	1.7	0.61	4.71	0.308	APOB	0.86	0.41	1.81	0.694
CDH10	1.52	0.65	3.52	0.33	SMAD4	0.88	0.47	1.66	0.698
TCF7L2	0.68	0.3	1.54	0.351	APC	0.93	0.6	1.43	0.739
FAM123B	1.35	0.69	2.64	0.377	ADARB2	1.14	0.41	3.15	0.796
MACF1	1.5	0.6	3.73	0.387	ATM	0.91	0.44	1.88	0.801
BCL9	0.54	0.13	2.21	0.394	BRAF	0.93	0.44	1.95	0.844
TP53	1.22	0.77	1.95	0.395	FBXW7	0.95	0.58	1.57	0.846
PRDM9	0.66	0.24	1.8	0.416	LRP1B	1.03	0.57	1.84	0.932
TET2	0.62	0.19	2	0.423	PTPRS	1.02	0.47	2.23	0.953
TMEM132D	1.39	0.6	3.2	0.439	FLNC	0.98	0.43	2.24	0.955
DOCK2	1.39	0.6	3.21	0.442	ARID1A	0.98	0.45	2.15	0.968
NF1	1.43	0.57	3.56	0.445	PIK3CA	1.01	0.62	1.64	0.97
PTEN	1.31	0.63	2.74	0.473

Abbreviations: LCL, lower confidence limit; UCL, upper confidence limit.

^a Adjusted for treatment arm (capecitabine/S‐1), age (older or younger than 65 years), sex, tumor depth (T0, T1, T2/T3/T4), nodal status (N1/N2), and tumor location (right‐sided/left‐sided). Genes with a gene mutation frequency of ≥3% were targeted for this analysis.